Herzich Paul

Chief Technology OfficerSolid Biosciences Inc. (SLDB) · full profile →Form 4 · filed Feb 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$169K
Net Open-Market Flow
-$169K
Transactions
7
3 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 2, 2026Sell(S)26K$6.44$169K80K
Jan 31, 2026Option exercise(M)25K106K
Jan 29, 2026Option exercise(M)55K82K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 31, 2026Option exercise(M)25K$074K
Jan 29, 2026Grant(A)85K$085K
Jan 29, 2026Option exercise(M)55K$00
Jan 29, 2026Grant(A)170K$0170K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-034076) within minutes of acceptance. Every field above traces to the original document. Verify it directly: